We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!
0
Signin
countryflagCA

888-969-2592

RY 167.35 0.5467% TD 87.16 0.6699% SHOP 114.42 1.4722% CNR 155.62 0.4259% ENB 55.85 0.6306% CP 109.89 -0.1091% BMO 123.0 0.0651% TRI 228.4 -0.3751% CNQ 49.83 0.4435% BN 72.45 1.2296% ATD 73.62 -1.0484% CSU 4323.3101 0.1958% BNS 71.22 -0.3916% CM 82.35 0.3779% SU 53.7 0.2053% TRP 61.7 1.2305% NGT 71.55 -0.6526% WCN 248.14 1.0877% MFC 40.83 0.2701% BCE 45.71 -0.1311%

NervGen Pharma Corp

Healthcare CA NGEN

2.39CAD
-0.02(0.83%)

Last update at 2024-10-09T17:41:00Z

Day Range

2.392.43
LowHigh

52 Week Range

1.503.33
LowHigh

Fundamentals

  • Previous Close 2.41
  • Market Cap150.55M
  • Volume12450
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-19.67988M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.33

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -20.72228M -12.72658M -11.18614M -9.76561M -1.35848M
Minority interest - - - - -
Net income -20.72228M -12.72658M -11.18614M -9.76561M -1.35848M
Selling general administrative 6.34M 4.50M 5.03M 3.38M 0.58M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.12M 0.04M 0.04M 0.04M 0.02M
Ebit -23.02503M -12.81122M -11.19588M -9.86443M -1.35848M
Ebitda -20.09257M -11.33470M -11.15624M -9.82621M -1.33872M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -23.02503M -11.37733M -11.19588M -9.86443M -1.35848M
Other operating expenses - - - - -
Interest expense 0.51M 0.00000M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 0.20M 0.03M 0.02M 0.10M -
Net interest income -0.31320M -1.40448M 0.02M 0.10M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 23.03M 11.38M 11.20M 9.86M 1.36M
Cost of revenue - - - - -
Total other income expense net 2.62M 0.06M -0.00911M - -
Discontinued operations - - - - -
Net income from continuing ops -20.72228M -12.72658M -11.18614M -9.76561M -1.35848M
Net income applicable to common shares -20.72228M -12.72658M -11.18614M -9.76561M -1.35848M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 23.88M 17.90M 6.68M 6.77M 3.10M
Intangible assets 0.43M 0.47M 0.47M 0.51M 0.55M
Earning assets - - - - -
Other current assets 0.59M 0.36M 0.49M 1.98M -
Total liab 10.41M 1.08M 0.76M 0.92M 0.58M
Total stockholder equity 13.46M 16.82M 5.92M 5.84M 2.51M
Deferred long term liab - - - - -
Other current liab 6.73M 0.27M 0.16M - 0.13M
Common stock 57.41M 42.40M 22.95M 15.29M 3.85M
Capital stock 57.41M 42.40M 22.95M 15.29M 3.85M
Retained earnings -55.77090M -35.04862M -22.32204M -11.13590M -1.37030M
Other liab - - - - 0.13M
Good will - - - - -
Other assets - - - - -
Cash 22.45M 16.93M 5.60M 4.11M 2.47M
Cash and equivalents - - - - -
Total current liabilities 10.22M 1.08M 0.76M 0.92M 0.45M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 11.82M 9.46M 5.30M 1.68M 0.04M
Property plant equipment 0.30M 0.00269M 0.00200M - -
Total current assets 23.15M 17.42M 6.20M 6.26M 2.55M
Long term investments - - - - -
Net tangible assets 13.03M 16.35M 5.45M 5.33M 1.97M
Short term investments - - - - -
Net receivables 0.03M 0.06M 0.06M 0.12M 0.03M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 2.00M 0.35M 0.17M 0.50M 0.05M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 0.51M 0.55M
Deferred long term asset charges - - - - -
Non current assets total 0.73M 0.48M 0.47M 0.51M 0.55M
Capital lease obligations 0.28M - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.02110M -0.04509M -0.00342M 0.00000M -0.12682M
Change to liabilities 2.32M 0.32M -0.16508M 0.24M 0.27M
Total cashflows from investing activities -0.02110M -0.04509M -0.00342M -0.00342M -0.12682M
Net borrowings -0.07569M -0.07569M -0.07569M -0.07569M -
Total cash from financing activities 22.64M 19.61M 7.85M 9.84M 3.59M
Change to operating activities -0.24233M 0.11M 1.52M 0.06M 0.06M
Net income -20.72228M -12.72658M -11.18614M -9.76561M -1.35848M
Change in cash 5.52M 11.33M 1.50M 1.63M 2.47M
Begin period cash flow 16.93M 5.60M 4.11M 2.47M 0.00000M
End period cash flow 22.45M 16.93M 5.60M 4.11M 2.47M
Total cash from operating activities -17.78416M -8.26916M -6.29772M -8.09396M -1.04008M
Issuance of capital stock 19.76M 18.90M 8.71M 10.74M 3.59M
Depreciation 0.12M 0.04M 0.04M 0.04M 0.02M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.04M -0.00141M 0.06M -0.09666M -0.02584M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.12904M -1.66627M -1.16921M -0.90079M -0.90079M
Change to netincome 0.71M 3.98M 3.43M 1.43M -0.00569M
Capital expenditures 0.02M 0.00275M 0.00342M 0.00342M 0.00342M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 2.11M 0.43M 1.41M 0.21M 0.30M
Stock based compensation 2.77M 4.02M 3.42M 1.29M -
Other non cash items 0.53M - - - -
Free cash flow -17.80527M -8.31424M -6.31028M -8.09396M -1.16689M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
NGEN
NervGen Pharma Corp		 -0.02 0.83% 2.39 - - - 29.48 -6.9477
ARCH
Arch Biopartners Inc		 -0.1 5.29% 1.79 - - 37.82 - 53.05 -28.1027
MIR
MedMira Inc		 - -% 0.09 - - 170.46 - 189.94 -48.7372
TTI
Thiogenesis Therapeutics Corp.		 - -% 0.67 - - - 11.86 -163.0787
SBM
Sirona Biochem Corp		 - -% 0.08 - - 343.74 41.64 359.74 -13.882

Reports Covered

Stock Research & News

View All

Profile

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

NervGen Pharma Corp

2955 Virtual Way, Vancouver, BC, Canada, V5M 4X6

Key Executives

Name Title Year Born
Mr. William Joseph Radvak BASc Co-Founder, Interim CEO & Exec. Chairman 1963
Dr. Harold Martin Punnett D.M.D. Co-Founder & Independent Director NA
Mr. William J. Adams C.A., CPA, CA, CPA CFO & Corp. Sec. 1962
Dr. Daniel D. Mikol M.D., Ph.D. Chief Medical Officer NA
Dr. Adam H. Rogers M.D. Interim Pres & Director NA
Mr. Brian McAlister Co-Founder & Advisor NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.